SEC Form 4 · accession 0000899243-17-002148
Wave Life Sciences, Inc. · WVE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Chandra Vargeese
Officer — See Remarks
Period of report
Jan 25, 2017
Accepted (ET)
Jan 27, 2017 · 6:17 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631574
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Jan 25, 2017 | A | 9,800 | $0.00 | A | 9,800 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share Option (right to buy)F2 | $29.05 | Jan 25, 2017 | A | 19,500 | A | — | Jan 25, 2027 | Ordinary Shares | 19,500 | 19,500 | D |
Explanation of responses
- F1Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 15, 2018, through February 15, 2021.
- F2The option vests as to 25% of the shares on February 15, 2018 and vests as to an additional 2.0833% of the shares monthly thereafter until February 15, 2021.
Remarks
Senior Vice President, Drug Discovery